Valuation: Nektar Therapeutics

Market Cap 206.72Cr 183.85Cr 171.76Cr 156.65Cr 294.01Cr 20TCr 298.36Cr 2.08TCr 804.45Cr 10TCr 776.08Cr 759.2Cr 33TCr P/E 2026 *
-7.49x
P/E 2027 * -5.91x
Enterprise Value 197.92Cr 176.02Cr 164.45Cr 149.98Cr 281.49Cr 19TCr 285.65Cr 1.99TCr 770.19Cr 9.72TCr 743.04Cr 726.87Cr 31TCr EV / Sales 2026 *
47.3x
EV / Sales 2027 * 32.6x
Free-Float
99.62%
Yield 2026 *
-
Yield 2027 * -
1 day-22.39%
1 week-18.51%
Current month-22.39%
1 month-34.17%
3 months-32.69%
6 months-34.69%
Current year+11.14%
1 week 46.29
Extreme 46.29
62.4
1 month 46.29
Extreme 46.29
77.76
Current year 33.4
Extreme 33.4
109
1 year 33.4
Extreme 33.4
109
3 years 6.19
Extreme 6.188996
109
5 years 6.19
Extreme 6.188996
280.35
10 years 6.19
Extreme 6.188996
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Date Insider Type Main position Quantity % Market Cap. Importance
23/09/26 Free

Director

6,000 0.0176%
23/09/26 Free

Director

6,000 0.0176%
23/09/26 Free

Director

6,000 0.0176%
Change 5-day change 1-year change 3-year change Capi.($)
-22.39%-18.51%-17.42%+425.97% 206.72Cr
+4.16%-0.36%+49.37%+94.17% 7.45TCr
-0.61%+0.69%+36.36%+82.72% 6.01TCr
-2.54%-0.21%+6.34%+31.72% 4.82TCr
-3.02%-2.67%+37.26%+32.51% 4.43TCr
+0.31%+7.94%+340.88%+643.82% 4.4TCr
-1.96%-1.71%+5.30%+99.46% 4.16TCr
+3.32%+3.49%+11.18%+51.23% 3TCr
+4.77%+6.16%+36.77%+22.78% 2.93TCr
-4.86%-8.24%-24.60%+330.06% 2.49TCr
Average -2.28%+2.27%+48.14%+181.45% 3.99TCr
Weighted average by Cap. +0.05%+1.85%+59.66%+147.23%

Financials

2026 *2027 *
Net sales 4.19Cr 3.72Cr 3.48Cr 3.17Cr 5.96Cr 403.32Cr 6.04Cr 42Cr 16Cr 205.59Cr 16Cr 15Cr 661.1Cr 5.7Cr 5.07Cr 4.74Cr 4.32Cr 8.11Cr 548.93Cr 8.23Cr 57Cr 22Cr 279.82Cr 21Cr 21Cr 899.77Cr
Net income -24Cr -22Cr -20Cr -19Cr -35Cr -2.36TCr -35Cr -245.78Cr -95Cr -1.2TCr -92Cr -90Cr -3.86TCr -35Cr -31Cr -29Cr -27Cr -50Cr -3.41TCr -51Cr -355.34Cr -137.66Cr -1.74TCr -132.81Cr -129.92Cr -5.58TCr
Net Debt -8.8Cr -7.83Cr -7.31Cr -6.67Cr -13Cr -847.71Cr -13Cr -88Cr -34Cr -432.12Cr -33Cr -32Cr -1.39TCr -21Cr -19Cr -17Cr -16Cr -30Cr -2.03TCr -30Cr -211.32Cr -82Cr -1.03TCr -79Cr -77Cr -3.32TCr
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
01/26/01 $46.99 -22.39% 61,12,526
30/26/30 $60.55 +2.20% 12,10,000
29/26/29 $59.24 -1.92% 18,16,418
28/26/28 $60.40 +5.85% 13,76,161
25/26/25 $57.06 -3.91% 26,36,139
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
46.99USD
Average target price
141.40USD
Spread / Average Target
+200.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock